Merck & Co.
Search results
For 175 years, Pfizer has been a trusted partner in healthcare – discovering, developing, and delivering medical breakthroughs to prevent, treat, and cure some of the world’s most vexing conditions and diseases.
News Releases. 03.06.2024. National Campaign Encourages Canadians to go “Out of Office” This Migraine Awareness Month. 03.06.2024. Pfizer invests $4.9M in McMaster University study to help improve care for multiple myeloma patients in Canada
The headquarters of Pfizer in Tokyo, Japan. Pfizer Inc. ( / ˈfaɪzər / FY-zər) [3] is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles ...
The Pfizer-BioNTech Comirnaty ® Original and Omicron BA.1, bivalent COVID-19 vaccine is approved as a booster for people who are 12 years of age and older. Its safety and effectiveness in younger people has not yet been established. Pfizer-BioNTech Comirnaty® Omicron XBB.1.5 subvariant, monovalent COVID-19 vaccine.
Help protect yourself with the latest Pfizer-BioNTech COVID-19 vaccine, COMIRNATY Omicron XBB.1.5.
1 day ago · NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment of adults with moderately severe to severe hemophilia A. The AFFINE study achieved its primary objective of non-inferiority, as well as superiority, of total annualized ...
23 hours ago · Pfizer Inc.’s gene therapy for a severe bleeding disorder met its goal in a pivotal late-stage trial, paving the way for the company to enter what’s proven to be a challenging market for drug ...
1 day ago · Pfizer's gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current ...
Dec 10, 2020 · Here, we report safety and efficacy findings from the phase 2/3 part of a global phase 1/2/3 trial evaluating the safety, immunogenicity, and efficacy of 30 μg of BNT162b2 in preventing Covid-19 ...
Feb 29, 2024 · Forward-Looking Statements of Pfizer Inc. This transcript may contain forward-looking statements about, among other things, our anticipated operating and financial performance, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, post-approval clinical ...
